Latest News & Features
Generics
Pfizer has sued Teva Pharmaceuticals, alleging that the Israeli pharma company is planning on releasing a generic of Pfizer’s Xeljanz XR arthritis treatment before the branded drug’s key patent expires. 17 February 2022
Big Pharma
Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end. 17 February 2022
Americas
A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified. 17 February 2022
Generics
Afrigen Biologics has used the publicly available information relating to Moderna’s COVID-19 vaccine to manufacture its own version of the treatment, which could see testing by the end of this year. 15 February 2022
Medtech
The US Court of Appeals for the Federal Circuit has affirmed two Patent Trial and Appeal Board rulings that a Johnson & Johnson subsidiary’s patent is valid and infringed. 15 February 2022
Americas
A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline. 14 February 2022
Generics
Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September. 10 February 2022
Biotechnology
Chiara Banas, patent scientist at EIP, queries the gender gap in life sciences, and shares how her own experiences could prefigure change. 10 February 2022
Africa
Humanitarian organisation Médecins Sans Frontières has called for the South African government to seek the revocation of COVID-19-related patents granted to Eli Lilly and Moderna. 10 February 2022
article
For decades the European Commission and EU member states have worked towards creating a pan-European Unified Patent Court. In August the German Constitutional Court issued a landmark decision taking us a step closer to this being a reality. Recent developments mean that the UPC is now in its Provisional Application Period, and companies will be deciding how to use the new system. 10 February 2022